Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Abbott Laboratories, short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An analysis of short-term operating activity ratios reveals several trends over the five-year period. Generally, the company demonstrates moderate stability in its operational efficiency, though some metrics indicate increasing strain on working capital management towards the later years of the period.

Inventory Management
Inventory turnover decreased consistently from 3.59 in 2021 to 2.98 in 2025. This suggests a growing inefficiency in managing inventory, potentially indicating overstocking, obsolescence, or weakening sales. Correspondingly, the average inventory processing period lengthened from 102 days in 2021 to 123 days in 2025, confirming the slower rate at which inventory is sold. A slight recovery in inventory turnover was observed in 2024, but this did not sustain into 2025.
Receivables Management
Receivables turnover initially increased from 6.64 in 2021 to 7.02 in 2022, indicating improved efficiency in collecting receivables. However, it then declined steadily to 5.59 in 2025. This decrease suggests a lengthening of the time required to collect payments from customers. The average receivable collection period increased from 55 days in 2021 to 65 days in 2025, corroborating this observation. The collection period remained stable at 60 days in both 2023 and 2024 before the final increase.
Payables Management
Payables turnover remained relatively stable between 4.15 and 4.56 over the period, with a slight upward trend in the latter years. The average payables payment period decreased from 87 days in 2021 and 2022 to 80 days in 2025, indicating the company is taking less time to pay its suppliers. This could be due to improved negotiation terms or a deliberate strategy to optimize cash flow.
Overall Operating Cycle & Cash Conversion Cycle
The operating cycle lengthened from 157 days in 2021 to 188 days in 2025, driven primarily by the increases in both inventory processing and receivable collection periods. The cash conversion cycle also increased, from 70 days in 2021 to 108 days in 2025. This indicates that the company is taking longer to convert its investments in inventory and receivables into cash. While the payables payment period decreased, this was insufficient to offset the increases in the other components of the cash conversion cycle.
Working Capital Turnover
Working capital turnover showed an initial improvement from 3.87 in 2021 to 4.54 in 2023, suggesting more efficient utilization of working capital. However, it decreased slightly to 4.42 in 2024 and then increased to 4.67 in 2025. This suggests a fluctuating, but ultimately improving, ability to generate sales from its working capital investments, though the trend is not consistently upward.

In summary, while the company maintains a reasonable level of operational activity, the lengthening of the inventory processing period, receivable collection period, and cash conversion cycle warrant attention. These trends suggest potential inefficiencies in working capital management that could impact future profitability and liquidity.


Turnover Ratios


Average No. Days


Inventory Turnover

Abbott Laboratories, inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
Intuitive Surgical Inc.
Medtronic PLC
Inventory Turnover, Sector
Health Care Equipment & Services
Inventory Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Inventory turnover = Cost of products sold, excluding amortization of intangible assets ÷ Inventories
= ÷ =

2 Click competitor name to see calculations.


The inventory turnover ratio exhibited a declining trend from 2021 to 2023, followed by a slight recovery in the subsequent two years. This indicates a changing efficiency in managing inventory levels relative to cost of goods sold.

Inventory Turnover Trend
The inventory turnover ratio decreased from 3.59 in 2021 to 3.10 in 2022, representing a 13.6% decline. This downward trend continued into 2023, with the ratio falling to 2.74, a further 11.6% decrease from the prior year. A modest increase to 3.02 was observed in 2024, followed by a slight decrease to 2.98 in 2025.
Cost of Products Sold
Cost of products sold increased from US$18,537 million in 2021 to US$19,142 million in 2022, then decreased to US$17,975 million in 2023. It subsequently rose to US$18,706 million in 2024 and further to US$19,319 million in 2025. These fluctuations in cost of goods sold contribute to the observed changes in inventory turnover.
Inventory Levels
Inventories increased significantly from US$5,157 million in 2021 to US$6,173 million in 2022, a 19.8% increase. Inventory levels continued to rise in 2023, reaching US$6,570 million. A decrease to US$6,194 million was noted in 2024, followed by a further increase to US$6,488 million in 2025. The increases in inventory, coupled with the fluctuations in cost of goods sold, explain the initial decline in the inventory turnover ratio.

The stabilization of the inventory turnover ratio in 2024 and 2025 suggests that inventory management practices may be adjusting to the changes in cost of goods sold and overall inventory levels. However, the ratio remains below the level observed in 2021, indicating a potentially less efficient use of inventory capital compared to the beginning of the period.


Receivables Turnover

Abbott Laboratories, receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net sales
Trade receivables, less allowances
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
Receivables Turnover, Sector
Health Care Equipment & Services
Receivables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Receivables turnover = Net sales ÷ Trade receivables, less allowances
= ÷ =

2 Click competitor name to see calculations.


The receivables turnover ratio exhibited a fluctuating pattern over the five-year period. Initially, the ratio increased from 6.64 in 2021 to 7.02 in 2022, suggesting improved efficiency in collecting receivables. However, subsequent years witnessed a consistent decline, falling to 6.11 in 2023, 6.06 in 2024, and further to 5.59 in 2025.

Receivables Turnover Trend
The initial increase in receivables turnover in 2022 could be attributed to more effective credit and collection policies, or a change in sales terms. The subsequent and sustained decrease from 2023 through 2025 indicates a lengthening of the collection period. This could be due to several factors, including a shift in the customer base towards those with longer payment terms, a relaxation of credit standards, or potential issues with the collection process itself.

Net sales demonstrated an overall upward trend, with a dip in 2023 before recovering and exceeding the 2021 level by 2025. Despite this sales growth, the declining receivables turnover suggests that the company is becoming less efficient at converting these sales into cash. The increase in trade receivables balances, from US$6,487 million in 2021 to US$7,929 million in 2025, corroborates this observation.

Relationship to Net Sales
While net sales increased over the period, the decrease in receivables turnover suggests that the growth in receivables is outpacing the growth in sales. This divergence warrants further investigation to determine the underlying causes and potential impact on cash flow.

The consistent decline in receivables turnover from 2023 to 2025 is a notable trend. Continued monitoring of this ratio is recommended, along with a detailed analysis of the aging of receivables and the effectiveness of collection efforts. Understanding the reasons behind this decline is crucial for maintaining healthy cash flow and optimizing working capital management.


Payables Turnover

Abbott Laboratories, payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
Payables Turnover, Sector
Health Care Equipment & Services
Payables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Payables turnover = Cost of products sold, excluding amortization of intangible assets ÷ Trade accounts payable
= ÷ =

2 Click competitor name to see calculations.


The analysis of payables turnover reveals a generally stable pattern with a slight upward trend over the five-year period. While fluctuations exist, the ratio demonstrates consistent efficiency in managing supplier credit.

Payables Turnover Trend
The payables turnover ratio exhibited relative stability between 2021 and 2023, fluctuating between 4.15 and 4.21. A modest increase was observed in 2024, rising to 4.46, and continued into 2025, reaching 4.56. This indicates a gradual improvement in the speed at which obligations to suppliers are being settled.
Relationship to Cost of Products Sold
Cost of products sold experienced a general upward trajectory, with a slight dip in 2023. Despite this fluctuation in cost of products sold, trade accounts payable remained relatively consistent, ranging from US$4,195 million to US$4,607 million. The increase in payables turnover, particularly in the later years, suggests that the company is effectively managing its payment cycle in relation to its production costs.
Accounts Payable Management
Trade accounts payable demonstrated a slight decrease from 2022 to 2024, before stabilizing in 2025. This, coupled with the increasing payables turnover, suggests improved efficiency in managing supplier relationships and potentially leveraging favorable payment terms. The consistent levels of accounts payable, despite rising cost of products sold, indicate a proactive approach to maintaining financial flexibility.

Overall, the payables turnover ratio suggests a healthy and improving trend in the company’s short-term financial management. The observed increases in the ratio, alongside stable accounts payable levels, point to efficient utilization of supplier credit and effective control over payment obligations.


Working Capital Turnover

Abbott Laboratories, working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Net sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
Working Capital Turnover, Sector
Health Care Equipment & Services
Working Capital Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Working capital turnover = Net sales ÷ Working capital
= ÷ =

2 Click competitor name to see calculations.


The working capital turnover ratio exhibited an overall increasing trend between 2021 and 2025, with some fluctuation. This indicates changes in the efficiency with which the company utilizes its working capital to generate sales.

Working Capital
Working capital decreased from US$11,134 million in 2021 to US$8,829 million in 2023, representing a substantial decline. It then experienced a modest recovery, reaching US$9,499 million in 2024 and stabilizing at US$9,500 million in 2025. This suggests a period of working capital reduction followed by stabilization.
Net Sales
Net sales demonstrated relative stability between 2021 and 2023, fluctuating around US$43 billion. A decrease was observed in 2023, followed by a recovery in 2024 and further growth to US$44,328 million in 2025. This indicates a rebound in sales performance towards the end of the analyzed period.
Working Capital Turnover
The working capital turnover ratio increased from 3.87 in 2021 to 4.48 in 2022, suggesting improved efficiency in utilizing working capital. It continued to rise to 4.54 in 2023, despite the decline in working capital and net sales. A slight decrease to 4.42 was noted in 2024, before increasing again to 4.67 in 2025, representing the highest value within the observed period. The ratio’s increase, despite the initial decrease in working capital, suggests improved sales generation per dollar of working capital invested. The final increase in 2025, coinciding with increased net sales, reinforces this positive trend.

The combined trends suggest that the company initially improved its efficiency in converting working capital into sales, even as working capital levels decreased. The stabilization of working capital and subsequent increase in net sales in the later years further contributed to the improved turnover ratio.


Average Inventory Processing Period

Abbott Laboratories, average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Intuitive Surgical Inc.
Medtronic PLC
Average Inventory Processing Period, Sector
Health Care Equipment & Services
Average Inventory Processing Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average inventory processing period exhibited an increasing trend over the observed period, while inventory turnover demonstrated a contrasting pattern. A detailed examination of these metrics reveals shifts in the efficiency of inventory management.

Average Inventory Processing Period
The average inventory processing period lengthened from 102 days in 2021 to a peak of 133 days in 2023. This indicates that, on average, inventory was held for a longer duration during this timeframe. A slight decrease was noted in 2024, with the period falling to 121 days, followed by a further increase to 123 days in 2025. The overall trend suggests a growing inefficiency in converting inventory into sales, or potentially a strategic shift towards holding larger inventory levels.
Inventory Turnover
Inventory turnover decreased from 3.59 in 2021 to 2.74 in 2023. This decline aligns with the increasing average inventory processing period, suggesting a slower rate of inventory depletion. A modest recovery occurred in 2024, with turnover rising to 3.02, but this improvement was not sustained, as turnover settled at 2.98 in 2025. The lower turnover rates indicate that the company sold and replenished its inventory fewer times during the later years of the period compared to the beginning.

The concurrent movements in these ratios suggest a potential relationship. The increasing time to process inventory appears to be inversely related to the rate at which inventory is turned over. Further investigation would be required to determine the underlying causes of these trends, such as changes in product mix, supply chain disruptions, or shifts in sales patterns.


Average Receivable Collection Period

Abbott Laboratories, average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
Average Receivable Collection Period, Sector
Health Care Equipment & Services
Average Receivable Collection Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average receivable collection period exhibited an increasing trend over the five-year period examined. While receivables turnover demonstrated fluctuation, the collection period consistently rose, suggesting a lengthening in the time required to convert accounts receivable into cash.

Average Receivable Collection Period
The average receivable collection period began at 55 days in 2021. A slight decrease was observed in 2022, falling to 52 days. However, from 2022 onward, the period increased steadily, reaching 60 days in both 2023 and 2024, and further increasing to 65 days in 2025. This indicates a growing inefficiency in collecting receivables.

The receivables turnover ratio, while showing some variability, generally declined over the period. This decline in turnover aligns with the increasing collection period, reinforcing the observation of a slowdown in the rate at which receivables are being collected. The ratio decreased from 6.64 in 2021 to 5.59 in 2025.

Relationship between Ratios
The inverse relationship between the receivables turnover ratio and the average receivable collection period is evident. As turnover decreased, the collection period increased, confirming that the company is taking longer to collect on its credit sales. This could be due to changes in credit policies, customer payment behavior, or collection efforts.

The consistent increase in the average receivable collection period warrants further investigation. Potential areas of inquiry include changes in the company’s credit terms, the aging of accounts receivable, and the effectiveness of collection procedures. A prolonged collection period ties up working capital and increases the risk of bad debts.


Operating Cycle

Abbott Laboratories, operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
Intuitive Surgical Inc.
Medtronic PLC
Operating Cycle, Sector
Health Care Equipment & Services
Operating Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle has demonstrated a generally increasing trend over the five-year period. Examination of the component ratios reveals the drivers behind this overall change.

Average Inventory Processing Period
The average inventory processing period exhibited an upward trend from 102 days in 2021 to 133 days in 2023. A slight decrease to 121 days was noted in 2024, followed by a further increase to 123 days in 2025. This suggests a lengthening time required to convert inventory into finished goods and make them available for sale, with a recent stabilization.
Average Receivable Collection Period
The average receivable collection period remained relatively stable between 2021 and 2023, fluctuating between 52 and 60 days. A consistent increase was observed in the final two years, rising to 60 days in 2024 and 65 days in 2025. This indicates a gradual lengthening in the time taken to collect payments from customers.
Operating Cycle
The operating cycle increased from 157 days in 2021 to a peak of 193 days in 2023. A decrease to 181 days occurred in 2024, but the cycle length increased again to 188 days in 2025. The increase in the operating cycle is attributable to the combined effect of the lengthening inventory processing and receivable collection periods. The slight dip in 2024 suggests some improvement in efficiency, but this was not sustained into 2025.

The combined trends suggest a potential slowdown in the efficiency of working capital management. While the increase is not dramatic, continued monitoring of these ratios is warranted to identify any further deterioration and to assess the need for operational improvements.


Average Payables Payment Period

Abbott Laboratories, average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
Average Payables Payment Period, Sector
Health Care Equipment & Services
Average Payables Payment Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average payables payment period exhibited a generally decreasing trend over the five-year period examined. While payables turnover showed some fluctuation, the associated payment period demonstrated a consistent, albeit modest, reduction.

Payables Turnover
Payables turnover remained relatively stable between 2021 and 2023, fluctuating around 4.2. An increase was observed in 2024, reaching 4.46, and continued into 2025 with a value of 4.56. This suggests a slight improvement in the efficiency with which obligations to suppliers were being settled during the latter part of the period.
Average Payables Payment Period
The average payables payment period began at 87 days in 2021, increased slightly to 88 days in 2022, and then returned to 87 days in 2023. A noticeable decrease occurred in 2024, falling to 82 days, and continued downward to 80 days in 2025. This indicates a shortening of the time taken to pay suppliers, potentially reflecting improved cash management practices or negotiated payment terms.
Relationship between Ratios
The inverse relationship between payables turnover and the average payables payment period is evident. As payables turnover increased, the average payment period decreased, confirming the expected correlation. The consistent decrease in the payment period, despite relatively stable turnover for the first three years, suggests factors beyond simply increased purchasing activity were at play, such as more efficient payment processing or supplier agreements.

Overall, the observed trends suggest a strengthening of the company’s financial position with respect to supplier payments, characterized by a more efficient use of credit terms and potentially improved relationships with vendors.


Cash Conversion Cycle

Abbott Laboratories, cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Intuitive Surgical Inc.
Medtronic PLC
Cash Conversion Cycle, Sector
Health Care Equipment & Services
Cash Conversion Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


An examination of short-term operating activity reveals evolving trends in the management of inventory, receivables, and payables. The cash conversion cycle, a key indicator of operational efficiency, demonstrates a generally increasing pattern over the observed period, though with some fluctuation.

Average Inventory Processing Period
The average number of days to process inventory exhibited an upward trend from 102 days in 2021 to a peak of 133 days in 2023. A slight decrease to 121 days was noted in 2024, followed by a further increase to 123 days in 2025. This suggests a growing period required to convert raw materials into finished goods, potentially indicating inefficiencies in inventory management or increased complexity in the supply chain.
Average Receivable Collection Period
The average number of days to collect receivables remained relatively stable between 2021 and 2022, at 55 and 52 days respectively. An increase to 60 days was observed in 2023, holding steady in 2024, and then increasing further to 65 days in 2025. This lengthening collection period could indicate a need to review credit policies or collection efforts.
Average Payables Payment Period
The average number of days to pay suppliers remained consistent around 87-88 days from 2021 to 2023. A decrease to 82 days was observed in 2024, followed by a further reduction to 80 days in 2025. This suggests improved management of payment terms with suppliers, potentially leveraging early payment discounts or optimizing cash flow.
Cash Conversion Cycle
The cash conversion cycle increased from 70 days in 2021 to 82 days in 2022. A significant increase to 106 days occurred in 2023, decreasing slightly to 99 days in 2024, and then rising again to 108 days in 2025. This overall upward trend indicates that the company is taking longer to convert its investments in inventory and other resources into cash. The increases in both inventory processing and receivable collection periods appear to be the primary drivers of this lengthening cycle, partially offset by the decreasing payables payment period.

In summary, while improvements in payable management are evident, the increasing trends in inventory processing and receivable collection are contributing to a longer cash conversion cycle. Continued monitoring of these ratios is recommended to identify potential areas for operational improvement and optimize working capital management.